Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

356 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
History of the development of azole derivatives.
Maertens JA. Maertens JA. Clin Microbiol Infect. 2004 Mar;10 Suppl 1:1-10. doi: 10.1111/j.1470-9465.2004.00841.x. Clin Microbiol Infect. 2004. PMID: 14748798 Free article. Review.
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group. Maertens J, et al. Clin Infect Dis. 2004 Dec 1;39(11):1563-71. doi: 10.1086/423381. Epub 2004 Nov 9. Clin Infect Dis. 2004. PMID: 15578352 Clinical Trial.
The place for itraconazole in treatment.
Maertens J, Boogaerts M. Maertens J, et al. J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i33-i38. doi: 10.1093/jac/dki222. J Antimicrob Chemother. 2005. PMID: 16120632 Review.
Preemptive antifungal therapy: still a way to go.
Maertens J, Deeren D, Dierickx D, Theunissen K. Maertens J, et al. Curr Opin Infect Dis. 2006 Dec;19(6):551-6. doi: 10.1097/QCO.0b013e3280106854. Curr Opin Infect Dis. 2006. PMID: 17075330 Review.
Invasive aspergillosis in the intensive care unit.
Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Meersseman W, et al. Clin Infect Dis. 2007 Jul 15;45(2):205-16. doi: 10.1086/518852. Epub 2007 Jun 13. Clin Infect Dis. 2007. PMID: 17578780 Review.
New therapies for fungal pneumonia.
Maertens J, Meersseman W, Van Bleyenbergh P. Maertens J, et al. Curr Opin Infect Dis. 2009 Apr;22(2):183-90. doi: 10.1097/QCO.0b013e328328cfff. Curr Opin Infect Dis. 2009. PMID: 19276884 Review.
Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
Herbrecht R, Patterson TF, Slavin MA, Marchetti O, Maertens J, Johnson EM, Schlamm HT, Donnelly JP, Pappas PG. Herbrecht R, et al. Clin Infect Dis. 2015 Mar 1;60(5):713-20. doi: 10.1093/cid/ciu911. Epub 2014 Nov 19. Clin Infect Dis. 2015. PMID: 25414266 Clinical Trial.
356 results